WallStreetZenWallStreetZen

NASDAQ: ALIM
Alimera Sciences Inc Stock

$3.34-0.10 (-2.91%)
Updated Apr 19, 2024
ALIM Price
$3.34
Fair Value Price
N/A
Market Cap
$174.86M
52 Week Low
$1.56
52 Week High
$4.38
P/E
-3.98x
P/B
3.79x
P/S
1.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$80.75M
Earnings
-$20.13M
Gross Margin
86.6%
Operating Margin
-12.21%
Profit Margin
-26.5%
Debt to Equity
2.33
Operating Cash Flow
-$14M
Beta
0.88
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALIM Overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALIM is poor value based on its book value relative to its share price (3.79x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.03x)
P/B vs Industry Valuation
ALIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALIM due diligence checks available for Premium users.

Be the first to know about important ALIM news, forecast changes, insider trades & much more!

ALIM News

Valuation

ALIM fair value

Fair Value of ALIM stock based on Discounted Cash Flow (DCF)
Price
$3.34
Fair Value
$5.81
Undervalued by
42.52%
ALIM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALIM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.98x
Industry
46.11x
Market
40.51x

ALIM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.79x
Industry
2.03x
ALIM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALIM's financial health

Profit margin

Revenue
$26.3M
Net Income
-$3.8M
Profit Margin
-14.4%
ALIM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALIM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$153.5M
Liabilities
$107.4M
Debt to equity
2.33
ALIM's short-term assets ($52.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALIM's long-term liabilities ($85.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALIM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$3.8M
Investing
-$85.0k
Financing
-$78.0k
ALIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALIM vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ALIM$174.86M-2.91%-3.98x3.79x
OGI$153.40M+1.07%N/A0.80x
LFCR$204.36M+5.94%-2.02x-48.31x
FTLF$132.75M-0.76%24.47x4.91x
ZOM$121.51M-3.88%-3.54x0.51x

Alimera Sciences Stock FAQ

What is Alimera Sciences's quote symbol?

(NASDAQ: ALIM) Alimera Sciences trades on the NASDAQ under the ticker symbol ALIM. Alimera Sciences stock quotes can also be displayed as NASDAQ: ALIM.

If you're new to stock investing, here's how to buy Alimera Sciences stock.

What is the 52 week high and low for Alimera Sciences (NASDAQ: ALIM)?

(NASDAQ: ALIM) Alimera Sciences's 52-week high was $4.38, and its 52-week low was $1.56. It is currently -23.74% from its 52-week high and 114.1% from its 52-week low.

How much is Alimera Sciences stock worth today?

(NASDAQ: ALIM) Alimera Sciences currently has 52,354,450 outstanding shares. With Alimera Sciences stock trading at $3.34 per share, the total value of Alimera Sciences stock (market capitalization) is $174.86M.

Alimera Sciences stock was originally listed at a price of $165.00 in Apr 22, 2010. If you had invested in Alimera Sciences stock at $165.00, your return over the last 13 years would have been -97.98%, for an annualized return of -25.92% (not including any dividends or dividend reinvestments).

How much is Alimera Sciences's stock price per share?

(NASDAQ: ALIM) Alimera Sciences stock price per share is $3.34 today (as of Apr 19, 2024).

What is Alimera Sciences's Market Cap?

(NASDAQ: ALIM) Alimera Sciences's market cap is $174.86M, as of Apr 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alimera Sciences's market cap is calculated by multiplying ALIM's current stock price of $3.34 by ALIM's total outstanding shares of 52,354,450.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.